FDA Approves Expanded Use of Lap-Band for Obese adults with a BMI of 30
FDA APPROVES EXPANDED USE OF LAP-BAND® ADJUSTABLE GASTRIC BANDING SYSTEM FOR OBESE ADULTS Obese Adults with a BMI of 30-40 with at Least One Obesity Related Comorbid Condition Now Qualify for LAP-BAND® System Procedure When All Other Conservative Weight-loss Therapies Have Failed
Obesity is the second-leading cause of preventable death in the United States, second only to smoking.
To view Lap Band Patient testimonials, visit our surgical site at https://www.surgicalartsinlandempire.com/lap-band-patient-story-1.html
Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of the LAP-BAND® System, Allergan’s gastric band, for adults with obesity who have failed more conservative weight reduction alternatives, such as diet and exercise and pharmacotherapy, and have a Body Mass Index (BMI) of 30-40 and at least one obesity related comorbid condition.
Currently, approximately 37 million Americans have a BMI of 30-40 and at least one comorbid condition,1,2 underscoring obesity as a growing health epidemic in the United States and the need for additional effective treatment options. 3 Given its known correlation to life-threatening comorbid conditions, such as heart disease, stroke, Type 2 diabetes, high blood pressure, sleep apnea and even premature death, obesity is a disease that requires medical treatment. Medical research has found that, if left untreated, those individuals who are currently obese will likely remain obese.4 However, not all weight-loss treatments are effective over the long term – as a preponderance of data, published literature and scientific research have found that diet and exercise is unsuccessful in 80-85% of patients at one year.5,6
To view Lap Band Patient testimonials, visit our surgical site at https://www.surgicalartsinlandempire.com/lap-band-patient-story-1.html